GES is excited to start the year with a bolstered product catalog with new products entering our approach offering to our clients (please download our latest product catalog here). We have already firmed up supply relationships, particularly in Australia, Germany, and the UK.
Our new offering for 2024 will be launching throughout Q2 of 2024 and includes a bolstered scaled supply chain of:
- Bulk or Packed Cannabis Flower
- THC Crude Oil
- THC Distillate
- Live Rosin
- Live Resin
- DAC Dronabinol: Bulk, Syringes, Oral Formulation 50ml
- Vape Cartridges: Distillate, Live Rosin, and Live Resin
- Oral Formulations: 200mg/ml CBD Isolate 30ml, 200mg/ml CBD Full-Spectrum 30ml, 25mg/ml CBD 25mg/ml THC 30ml, 15mg/ml THC 50ml
- Concentrates: 5g Live Hash/Temple Ball, 2g Live Rosin, 3g Live Resin
If you would like to receive samples for our products above, please enquire here.
Firstly, GES has entered into partnerships that will see an exciting development into placing a water-based (solventless) full-spectrum cannabis extract or “live rosin”. This novel active cannabinoid ingredient with innovative terpene and flavor characteristics will be available for compounding use cases, vape cartridges, and oral formulations. Our key value chain partnerships will be bolstering large quantities with the initial goal of producing min. 200 kgs of “live rosin” extract for the global medical cannabis market in 2024.
Our 12-month research and development programs have brought to market scaled supply chains of the most innovative, unique, and active-containing constituents for our clients this year.
We are also extremely excited about some breakthroughs in our value chain about the manufacture of DAC Dronabinol. Putting together a scalable validated manufacturing process for high purity, 98+%, APIs from natural sources, especially when the API is oxidized in the presence of air has proven to be a difficult task and a long journey. However, we are extremely excited about the recent breakthrough that will allow us to dig further into the world of registered generic APIs, particularly natural Dronabinol. This new validated process and products will be used as our base going into 2024 for an APIMF (Active Pharmaceutical Ingredient Master File) submission later this year, allowing us to register this API with our regulator, SAHPRA. This API is available for sale as a GMP Part 2 raw material and we are actively looking for partners in the fields of generic drug registration, clinical trials and university research and development. Please reach out for a sample today.
In preparation for a prosperous year at GES, January has been spent meticulously taking apart our technologies and performing a thorough deep routine maintenance as well as upgrading our existing utilities (heating/cooling) to provide larger capacities for API manufacturing as well as performing operational qualifications and stability batches for our new product launches in 2024.
As always, if you are looking for a partner that has a stable, scalable, and reliable value chain and technology platform – please feel free to contact us and find out more information from us.
We provide the best form of medicinal cannabis products, today, tomorrow, and well into the future.